Cargando…
Cost-Effectiveness of Pharmacotherapy to Reduce Obesity
AIMS: Obesity causes a high disease burden in Australia and across the world. We aimed to analyse the cost-effectiveness of weight reduction with pharmacotherapy in Australia, and to assess its potential to reduce the disease burden due to excess body weight. METHODS: We constructed a multi-state li...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203105/ https://www.ncbi.nlm.nih.gov/pubmed/22046255 http://dx.doi.org/10.1371/journal.pone.0026051 |
_version_ | 1782215073026015232 |
---|---|
author | Veerman, J. Lennert Barendregt, Jan J. Forster, Megan Vos, Theo |
author_facet | Veerman, J. Lennert Barendregt, Jan J. Forster, Megan Vos, Theo |
author_sort | Veerman, J. Lennert |
collection | PubMed |
description | AIMS: Obesity causes a high disease burden in Australia and across the world. We aimed to analyse the cost-effectiveness of weight reduction with pharmacotherapy in Australia, and to assess its potential to reduce the disease burden due to excess body weight. METHODS: We constructed a multi-state life-table based Markov model in Excel in which body weight influences the incidence of stroke, ischemic heart disease, hypertensive heart disease, diabetes mellitus, osteoarthritis, post-menopausal breast cancer, colon cancer, endometrial cancer and kidney cancer. We use data on effectiveness identified from PubMed searches, on mortality from Australian Bureau of Statistics, on disease costs from the Australian Institute of Health and Welfare, and on drug costs from the Department of Health and Ageing. We evaluate 1-year pharmacological interventions with sibutramine and orlistat targeting obese Australian adults free of obesity-related disease. We use a lifetime horizon for costs and health outcomes and a health sector perspective for costs. Incremental Cost-Effectiveness Ratios (ICERs) below A$50 000 per Disability Adjusted Life Year (DALY) averted are considered good value for money. RESULTS: The ICERs are A$130 000/DALY (95% uncertainty interval [UI] 93 000–180 000) for sibutramine and A$230 000/DALY (170 000–340 000) for orlistat. The interventions reduce the body weight-related disease burden at the population level by 0.2% and 0.1%, respectively. Modest weight loss during the interventions, rapid post-intervention weight regain and low adherence limit the health benefits. CONCLUSIONS: Treatment with sibutramine or orlistat is not cost-effective from an Australian health sector perspective and has a negligible impact on the total body weight-related disease burden. |
format | Online Article Text |
id | pubmed-3203105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32031052011-11-01 Cost-Effectiveness of Pharmacotherapy to Reduce Obesity Veerman, J. Lennert Barendregt, Jan J. Forster, Megan Vos, Theo PLoS One Research Article AIMS: Obesity causes a high disease burden in Australia and across the world. We aimed to analyse the cost-effectiveness of weight reduction with pharmacotherapy in Australia, and to assess its potential to reduce the disease burden due to excess body weight. METHODS: We constructed a multi-state life-table based Markov model in Excel in which body weight influences the incidence of stroke, ischemic heart disease, hypertensive heart disease, diabetes mellitus, osteoarthritis, post-menopausal breast cancer, colon cancer, endometrial cancer and kidney cancer. We use data on effectiveness identified from PubMed searches, on mortality from Australian Bureau of Statistics, on disease costs from the Australian Institute of Health and Welfare, and on drug costs from the Department of Health and Ageing. We evaluate 1-year pharmacological interventions with sibutramine and orlistat targeting obese Australian adults free of obesity-related disease. We use a lifetime horizon for costs and health outcomes and a health sector perspective for costs. Incremental Cost-Effectiveness Ratios (ICERs) below A$50 000 per Disability Adjusted Life Year (DALY) averted are considered good value for money. RESULTS: The ICERs are A$130 000/DALY (95% uncertainty interval [UI] 93 000–180 000) for sibutramine and A$230 000/DALY (170 000–340 000) for orlistat. The interventions reduce the body weight-related disease burden at the population level by 0.2% and 0.1%, respectively. Modest weight loss during the interventions, rapid post-intervention weight regain and low adherence limit the health benefits. CONCLUSIONS: Treatment with sibutramine or orlistat is not cost-effective from an Australian health sector perspective and has a negligible impact on the total body weight-related disease burden. Public Library of Science 2011-10-27 /pmc/articles/PMC3203105/ /pubmed/22046255 http://dx.doi.org/10.1371/journal.pone.0026051 Text en Veerman et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Veerman, J. Lennert Barendregt, Jan J. Forster, Megan Vos, Theo Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title | Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title_full | Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title_fullStr | Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title_full_unstemmed | Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title_short | Cost-Effectiveness of Pharmacotherapy to Reduce Obesity |
title_sort | cost-effectiveness of pharmacotherapy to reduce obesity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203105/ https://www.ncbi.nlm.nih.gov/pubmed/22046255 http://dx.doi.org/10.1371/journal.pone.0026051 |
work_keys_str_mv | AT veermanjlennert costeffectivenessofpharmacotherapytoreduceobesity AT barendregtjanj costeffectivenessofpharmacotherapytoreduceobesity AT forstermegan costeffectivenessofpharmacotherapytoreduceobesity AT vostheo costeffectivenessofpharmacotherapytoreduceobesity |